Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943238 · ClinicalTrials.gov registry record · Phase 1
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
A Phase 1 study, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03943238: Recruiting Phase 1 study, sponsored by Stanford University.
NCT03943238 is a Phase 1 study that is actively recruiting participants, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943238, a Phase 1 study, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow for eventual discontinuation of anti-rejection drugs after living donor kidney transplantation.
Interventions
- BIOLOGICAL Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943238
The ClinicalTrials.gov registry entry for NCT03943238 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs is the first listed.
NCT03943238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943238 about?
NCT03943238 is a clinical study titled "TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation". This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow for eventual discon...
What is the current status of trial NCT03943238?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-02-01. Estimated completion is 2029-12-01.
What interventions are being tested in trial NCT03943238?
The interventions under investigation include: Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs (BIOLOGICAL).
Who is sponsoring clinical trial NCT03943238?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.